Merkel Cell Carcinoma Treatments
Find Merkel Cell Carcinoma Treatments
Brand Name
ZYNYZ
Generic Name
Retifanlimab-Dlwr
View Brand Information FDA approval date: March 22, 2023
Classification: Programmed Death Receptor-1 Blocking Antibody
Form: Injection
What is ZYNYZ (Retifanlimab-Dlwr)?
ZYNYZ is a programmed death receptor-1 –blocking antibody indicated: Squamous Cell Carcinoma of the Anal Canal in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal .
Approved To Treat
Top Global Experts
Save this treatment for later
Not sure about your diagnosis?
Tired of the same old research?
Related Clinical Trials
There is no clinical trials being done for this treatment